BAP1 and cholangiocarcinoma: In contrast to BAP1, the presence of co-occurring TP53 alterations in tumors has previously been associated with a shorter overall survival and median progression-free survival in patients with cholangiocarcinoma treated with pemigatinib, compared with those without.19